Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlights eight publications in international journals that have confirmed that kinase-activity profiling can aid disease understanding and treatment development. These papers follow a late-2020 article in the Journal for ImmunoTherapy of Cancer on predicting immunotherapy response using the IOpener®, PamGene’s blood-based diagnostic test, with the company’s kinome activity profiling technology at its basis.
The scientific papers, presenting preclinical and clinical results in the fields of basic science, translational research and immunotherapy response prediction research, have been published in international peer-reviewed journals: Nature Communication, the International Journal of Cancer, Cancers (Basel), the European Journal of Cancer, Clinical Proteomics, Biomedicine Pharmacotherapy and the International Journal of Molecular Science and Molecules.
“The research presented in these publications underscores the value of measuring kinome activity using PamGene’s kinase-activity profiling platform, which can support scientists in understanding the role of cell signalling and developing better tools to guide cancer treatment,” says John Groten, managing director of PamGene.
Dr. Kristiane Schmidt, PamGene’s program manager IVD, highlights the impact of these publications. “The published data is powerful evidence that corroborates our IOpener® diagnostic platform’s technology. The IOpener® aims to predict immunotherapy response in oncological diseases by using kinase-activity profiling of peripheral blood mononuclear cells isolated from blood samples of patients eligible for immunotherapy.”
The publications are:
- Nielsen SR et al, Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade, Nat Commun. 2021 Jun 7;12(1):3414. doi: 10.1038/s41467-021-23731-7.
- Bussmann L et al., Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets, Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33606. Online ahead of print. PMID: 33890294
- Logie E et al., Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells, Cancers (Basel). 2021 Mar 31;13(7):1618. doi: 10.3390/cancers13071618. PMID: 33807411
- Tabbò F et al., Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways, Eur J Cancer. 2021 Feb;144:17-30. doi: 10.1016/j.ejca.2020.10.036. Epub 2020 Dec 11. PMID: 33316635
- Buffart TE et al., Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients, Clin Proteomics. 2021 Feb 18;18(1):8. doi: 10.1186/s12014-020-09306-6. PMID: 33602116
- Dayang EZ et al., Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation. Biomed Pharmacother. 2021 Jan;133:111073. doi: 10.1016/j.biopha.2020.111073. PMID: 33378972
- Roy A et al., Identification of Novel Substrates for cGMP Dependent Protein Kinase (PKG) through Kinase Activity Profiling to Understand Its Putative Role in Inherited Retinal Degeneration, Int J Mol Sci. 2021 Jan 25;22(3):1180. doi: 10.3390/ijms22031180. PMID: 33503999
- Abdalla AN et al., Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer, Molecules. 2021 Jan 11;26(2):334. doi: 10.3390/molecules26020334. PMID: 33440689
- Hurkmans DP et al., Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer, J Immunother Cancer. 2020 Dec;8(2):e001607. doi: 10.1136/jitc-2020-001607.
About IOpener® – A liquid biopsy immunotherapy treatment selection test that improves lives
The IOpener® is a blood-based diagnostic test that supports immunotherapy treatment selection. This peptide microarray-based test measures the activity of kinases in peripheral blood mononuclear cell isolated from a single tube of blood from a patient to determine the likelihood of responding to immunotherapy. The test’s technology is based on 20 years of experience in measuring and interpreting kinase activity to support academic and clinical research. The IOpener® test is an in-house developed test that will be performed in PamGene’s ISO 13485:2016 certified laboratory. The IOpener® is in the final phase of clinical validation for CE-IVD certification.
About PamGene
PamGene International B.V. is an in-vitro diagnostics company which has recently intensified its efforts to develop and commercialize a blood-based immunotherapy selection test, the IOpener®, to improve patient lives. The company’s kinase-activity profiling technology and proprietary software algorithms support clinicians in their treatment decisions using the IOpener® assay. PamGene’s robust and unique peptide microarray technology for multiplex kinase-activity profiling is also used to provide dedicated assay services for patient stratification for clinical trials, biomarker discovery and gaining mechanistic insights in cellular processes needed to understand human diseases. PamGene was founded in 1999 and is headquartered in ‘s-Hertogenbosch, the Netherlands.
For more information, please contact Rinie van Beuningen, Vice President Business Development – iopener@pamgene.com – +31 (0) 73 615 80 80 – www.pamgene.com.
IOpener® is a registered trademark in the U.S. and European Union.